儿童肿瘤发热伴中性粒细胞减少且证实呼吸道病毒感染时停用抗菌药物治疗的有效性与安全性:一项随机临床试验
在智利7家医院开展前瞻性、多中心、非劣效性随机试验,939例儿童肿瘤发热伴中性粒细胞减少(FN)中301例仅检出呼吸道病毒,其中139例在抗菌治疗48-72小时后病情稳定者随机分为维持治疗组(70例)与停用组(69例)。两组无事件缓解率相似(66/70 vs 66/69,相对风险1.01,95%CI 0.93-1.09),无脓毒症、PICU入住或死亡。
要点
- 儿童肿瘤FN且仅检出呼吸道病毒、抗菌治疗48-72小时后病情稳定者可考虑停用抗菌药物。
- 停用组与维持组无事件缓解率相似,相对风险1.01(95%CI 0.93-1.09),绝对风险差0.01(95%CI -0.05至0.08)。
- 两组均无脓毒症、PICU入住或死亡病例报告。
核心结论
- 基于临床和微生物/分子诊断标准,验证了在FN且呼吸道病毒感染的儿童中停用抗菌药物的策略。
- 该策略可能促进抗菌药物管理策略的进步,并可能对未来抗菌药物耐药产生影响。
研究设计与样本
- 前瞻性、多中心、非劣效性随机研究,经伦理委员会批准,在智利7家医院开展。
- 939例FN患儿入院时评估细菌和病毒病原体,301例仅检出呼吸道病毒,其中139例在抗菌治疗48-72小时后病情稳定者被随机分组。
- 139例随机分为维持抗菌治疗组(70例)和停用抗菌治疗组(69例)。
主要发现
- 抗菌治疗中位天数维持组5天(IQR 3-6)vs 停用组3天(IQR 3-6),p < 0.001。
- 无事件缓解率维持组66/70(94%)vs 停用组66/69(96%),相对风险1.01(95%CI 0.93-1.09),绝对风险差0.01(95%CI -0.05至0.08)。
- 两组发热天数和住院天数相似。
- 未报告脓毒症、PICU入住或死亡病例。
关键数值与推荐
- 入组条件:FN患儿,呼吸道病毒阳性,细菌病原体阴性,抗菌治疗48-72小时后病情稳定。
- 主要终点:无事件缓解的 episode 百分比;次要终点:发热天数、住院天数、需重新使用抗菌药物、脓毒症、PICU入住和死亡。
临床怎么用
- 作者认为,基于临床和微生物/分子诊断标准,在FN且呼吸道病毒感染的儿童中停用抗菌药物的策略得到验证。
- 作者指出,该策略可能促进抗菌药物管理策略的进步,并可能对未来抗菌药物耐药产生影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To validate the efficacy and safety of withholding antimicrobial therapy in a new cohort of children with cancer and febrile neutropenia (FN) having a demonstrated viral respiratory tract infection. METHODS: Prospective, multicenter, noninferiority, randomized study, approved by the ethical committee, in children presenting with FN at seven hospitals in Chile, evaluated at admission for diagnosis of bacterial and viral pathogens. Children who were positive for a respiratory virus, negative for a bacterial pathogen, and had a favourable evolution after 48-72 hours of antimicrobial therapy were randomized to either maintain or withhold antimicrobial therapy. The primary endpoint was the percentage of episodes with an uneventful resolution, whereas the secondary endpoints were days of fever, days of hospitalization, requirement of antimicrobial treatment readministration, sepsis, paediatric intensive care unit admission, and death. RESULTS: A total of 301 of 939 children with FN episodes recruited between March 2021 and December 2023 had a respiratory virus as a unique identified microorganism, of which 139 had a favourable evolution at 48-72 hours and were randomized, 70 to maintain and 69 to withdraw antimicrobial therapy. The median days of antimicrobial therapy was 5 (IQR 3-6) versus 3 (IQR 3-6) days (p < 0.001), with similar frequency of uneventful resolution 66/70 (94%) and 66/69 (96%); relative risk, 1.01; (95% CI, 0.93 to 1.09), absolute risk difference 0.01; (95% CI, -0.05 to 0.08) and similar number of days of fever and days of hospitalization. No cases of sepsis, paediatric intensive care unit admission, or death were reported. DISCUSSION: We validated the strategy of withdrawal antimicrobial therapy in children with FN and viral respiratory tract infection based on clinical and microbiological/molecular diagnostic criteria. This will enable advances in antimicrobial stewardship strategies with a possible future impact on antimicrobial resistance.
引用
- Torres JP, Ibañez C, Valenzuela R, et al. Efficacy and safety of withholding antimicrobial therapy in children with cancer, fever, and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial. Clin Microbiol Infect. 2024. PMID: 38648896. doi:10.1016/j.cmi.2024.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。